In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.

Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.

Magazine

Noventure's Participation in 2018 EAU congress

For the third consecutive year, Noventure has participated in the annual congress of the EAU - European Association of Urology that took place in Copenhagen 17th – 19th March 2018 with about 11,000 participants, coming from 123 countries all over the world. During the Congress 273 scientific sessions included 2,656 presentations of cutting-edge urological updates presented by 1,830 international experts.

Noventure participated in this congress with a 28 m2 stand to assess its presence in the urology field thanks to its medical device UTIPRO PLUS intended to control and prevent uncomplicated UTIs.

Read more
Antibiotic-Resistant Infection Treatment Costs Have Doubled Since 2002, Now Exceeding $2 Billion Annually.

Kenneth Thorpe, from Emery University in Atlanta, and his colleagues found in a study carried out in the USA, that while the overall number of bacterial infections remained relatively constant between 2002 and 2014, rising from 13.5 million to 14.3 million annually, the proportion that were antibiotic-resistant rose dramatically, from 5.2% to 11.0%. Patients with antibiotic-resistant infections had spending for bacterial infection that was 165 percent higher than spending by patients without such infections. Sixty-one percent of antibiotic-resistant infections were associated with urinary tract infections. Their conclusion is that the direct costs and the mortality and morbidity attributable to antibiotic-resistant infections make a compelling case for urgent action by national and international policy makers.

Read more
Utipro® Plus Launched In France

We are pleased to announce the launch in France of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is commercialized over the French territory under the umbrella brand Cysticare / Utipro plus and is distributed by Vemedia, our partner for the product in the Netherlands as well.

Read more